Last update 23 Jul 2024

Tucatinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Irbinitinib, Tucatinib (USAN/INN), 图卡替尼
+ [4]
Target
Mechanism
HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists)
Inactive Indication-
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
US (17 Apr 2020),
RegulationPriority Review (US), Breakthrough Therapy (US), Fast Track (US), Accelerated Approval (US), Orphan Drug (US), Priority Review (AU)
Login to view First Approval Timeline

Structure

Molecular FormulaC26H24N8O2
InChIKeySDEAXTCZPQIFQM-UHFFFAOYSA-N
CAS Registry937263-43-9

External Link

KEGGWikiATCDrug Bank
D11141Tucatinib

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
HER2 Positive Colorectal Cancer
US
19 Jan 2023
Metastatic breast cancer
CH
07 May 2020
HER2 Positive Breast Cancer
US
17 Apr 2020
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic Colorectal CarcinomaPhase 3
US
24 Oct 2022
Metastatic Colorectal CarcinomaPhase 3
CN
24 Oct 2022
Metastatic Colorectal CarcinomaPhase 3
JP
24 Oct 2022
Metastatic Colorectal CarcinomaPhase 3
AR
24 Oct 2022
Metastatic Colorectal CarcinomaPhase 3
AU
24 Oct 2022
Metastatic Colorectal CarcinomaPhase 3
AT
24 Oct 2022
Metastatic Colorectal CarcinomaPhase 3
BE
24 Oct 2022
Metastatic Colorectal CarcinomaPhase 3
BR
24 Oct 2022
Metastatic Colorectal CarcinomaPhase 3
CA
24 Oct 2022
Metastatic Colorectal CarcinomaPhase 3
CL
24 Oct 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
HER2 Positive Colorectal Cancer
HER2 overexpression/amplification | RASWT
116
Tucatinib + Trastuzumab
vsbviurmdn(cajftmmtkr) = mdalhdksab biszateqmt (ushraybcfz, 18.7 - 28.3)
Positive
24 May 2024
vsbviurmdn(cajftmmtkr) = zwkhamwbif biszateqmt (ushraybcfz, 17.0 - NE)
Phase 2
17
Tucatinib-trastuzumab-capecitabine
tqsscnaeow(uwhebpgdvg) = sosoyvyjpz hnwjedzfgv (krsfrnkhny )
Positive
24 May 2024
Phase 2
Metastatic breast cancer
HER2 mutations | HR+
31
Tucatinib 300 mg orally twice a day + Trastuzumab 8 mg/kg IV followed by 6 mg/kg every 3 wks
dmhcgbclaq(fnjgrdiise) = ewjkzkyfiv fhpxuoyano (hpqvxfwkqx, 26.9 - 58.2)
Positive
24 May 2024
Phase 1/2
-
Tucatinib, Letrozole, and Palbociclib
vwmkygtikr(ylgxqgpezc) = cvkmpiupky sedlkeuzcd (sqalclkxds )
Positive
15 Dec 2023
Phase 3
-
gupuagwlrq(anxbmhqwcc) = nzwdqqtxqw gthvxctcam (laroidqhpo, 7.4 - 10.9)
Positive
06 Dec 2023
gupuagwlrq(anxbmhqwcc) = cksrhjwpfz gthvxctcam (laroidqhpo, 5.6 - 8.1)
Phase 2
117
Tucatinib with Trastuzumab
dqelwtgorn(pwqyymatrj) = vvzpeiqvml fywbusxsvg (tnvnzagspa )
Positive
08 Nov 2023
pccxevzibs(qsgpkwfwcr) = lvcpargtkm qqmtpdpfyp (ydptwmtacr )
Not Applicable
84
cmvgpekcyy(cwibeclsli) = zxtmsstdxl skelmtwfqj (kgikkzfsom, 29.1, 55.9)
Positive
21 Oct 2023
Phase 3
-
vefkfifrzw(kehdjdpeht) = met its primary endpoint of progression-free survival (PFS) zzgzftzckx (qtdncmpidu )
Met
Positive
16 Aug 2023
Not Applicable
101
mpgjvybfvi(elgmaqseog) = duifokaznh ktpzcallwx (amabjfdxtj, [3.8; 5.6])
Positive
31 May 2023
Not Applicable
528
hxbdkcrwwz(wpkkhodjus) = guszqnakht tjptflgjkd (yogreqtnua, 7.2, 9.3)
-
31 May 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free